Medical Developments International (MVP) Stock Overview
Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MVP Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Medical Developments International Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.41 |
| 52 Week High | AU$0.77 |
| 52 Week Low | AU$0.36 |
| Beta | 1.39 |
| 1 Month Change | 6.41% |
| 3 Month Change | 1.22% |
| 1 Year Change | -31.69% |
| 3 Year Change | -62.27% |
| 5 Year Change | -90.86% |
| Change since IPO | -13.54% |
Recent News & Updates
Narrative Update • Jun 24
MVP: Higher Future P/E Assumptions Will Support Re Rating From Discount
Analysts have made a small upward adjustment to the A$ price target for Medical Developments International, reflecting updated fair value assumptions and a slightly higher future P/E expectation, despite more conservative inputs for discount rate, revenue growth and profit margin. What's in the News No recent news items for Medical Developments International were identified in the provided sources.
Narrative Update • Jun 10
MVP: Higher Margin Assumptions Will Support Future Upside Potential
Analysts have set a new A$ price target for Medical Developments International, reflecting slightly higher assumed revenue growth of 12.38% and profit margins of 14.25%, along with a modestly lower future P/E of 53.60 compared with the prior assumptions. What's in the News No recent news stories, periodical articles, or key developments were provided for Medical Developments International, so current publicly reported events are not available in this summary.Narrative Update • May 27
MVP: Higher Margin Assumptions Will Support Future Upside Potential
Analysts have updated their price target for Medical Developments International to A$3.21, reflecting small adjustments to revenue growth, profit margin and forward P/E assumptions in their models. Valuation Changes Fair Value: A$3.21 remains unchanged, indicating no revision to the central valuation output from the model.Narrative Update • May 11
MVP: Higher P/E Expectations Will Support Future Upside Potential
Analysts have slightly adjusted their price target for Medical Developments International to A$3.21 from A$3.18, reflecting modest updates to assumptions around discount rate, revenue growth, profit margin and future P/E expectations. Valuation Changes Fair Value: A$3.18 to A$3.21, reflecting a slight upward adjustment in the modelled estimate.Narrative Update • Apr 18
MVP: Higher Margin Outlook And Stable Discount Rate Will Support Future Upside Potential
Analysts have modestly lifted their price target for Medical Developments International to A$3.18, reflecting updated assumptions for revenue growth, profit margins and future P/E that are now slightly more supportive of the current valuation framework. Valuation Changes Fair Value: A$3.18 remains unchanged, so the updated work keeps the same central valuation anchor.Narrative Update • Apr 04
MVP: Higher Profitability Assumptions Will Still Support Attractive Future Upside Potential
Analysts have lifted the price target for Medical Developments International to A$3.18, reflecting updated assumptions that keep fair value steady while slightly adjusting revenue growth, profit margin and future P/E expectations. Valuation Changes Fair Value: Held steady at A$3.18, indicating no change in the central valuation estimate.Recent updates
Narrative Update • Jun 24
MVP: Higher Future P/E Assumptions Will Support Re Rating From Discount
Analysts have made a small upward adjustment to the A$ price target for Medical Developments International, reflecting updated fair value assumptions and a slightly higher future P/E expectation, despite more conservative inputs for discount rate, revenue growth and profit margin. What's in the News No recent news items for Medical Developments International were identified in the provided sources.Narrative Update • Jun 10
MVP: Higher Margin Assumptions Will Support Future Upside Potential
Analysts have set a new A$ price target for Medical Developments International, reflecting slightly higher assumed revenue growth of 12.38% and profit margins of 14.25%, along with a modestly lower future P/E of 53.60 compared with the prior assumptions. What's in the News No recent news stories, periodical articles, or key developments were provided for Medical Developments International, so current publicly reported events are not available in this summary.Narrative Update • May 27
MVP: Higher Margin Assumptions Will Support Future Upside Potential
Analysts have updated their price target for Medical Developments International to A$3.21, reflecting small adjustments to revenue growth, profit margin and forward P/E assumptions in their models. Valuation Changes Fair Value: A$3.21 remains unchanged, indicating no revision to the central valuation output from the model.Narrative Update • May 11
MVP: Higher P/E Expectations Will Support Future Upside Potential
Analysts have slightly adjusted their price target for Medical Developments International to A$3.21 from A$3.18, reflecting modest updates to assumptions around discount rate, revenue growth, profit margin and future P/E expectations. Valuation Changes Fair Value: A$3.18 to A$3.21, reflecting a slight upward adjustment in the modelled estimate.Narrative Update • Apr 18
MVP: Higher Margin Outlook And Stable Discount Rate Will Support Future Upside Potential
Analysts have modestly lifted their price target for Medical Developments International to A$3.18, reflecting updated assumptions for revenue growth, profit margins and future P/E that are now slightly more supportive of the current valuation framework. Valuation Changes Fair Value: A$3.18 remains unchanged, so the updated work keeps the same central valuation anchor.Narrative Update • Apr 04
MVP: Higher Profitability Assumptions Will Still Support Attractive Future Upside Potential
Analysts have lifted the price target for Medical Developments International to A$3.18, reflecting updated assumptions that keep fair value steady while slightly adjusting revenue growth, profit margin and future P/E expectations. Valuation Changes Fair Value: Held steady at A$3.18, indicating no change in the central valuation estimate.Narrative Update • Mar 21
MVP: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have reduced their price target for Medical Developments International to A$3.18 from A$3.73, citing updated assumptions for the discount rate, revenue growth, profit margins and future P/E, which result in a more conservative valuation view. Valuation Changes Fair Value: The analyst fair value estimate has moved from A$3.73 to A$3.18, reflecting a more conservative pricing assumption.Narrative Update • Mar 06
MVP: Stable Assumptions Will Support Future Re Rating From Current Discount
Analysts have maintained their fair value estimate for Medical Developments International at A$2.02 per share, with no change to growth, margin or P/E assumptions. This reflects an unchanged overall price target and thesis.Narrative Update • Feb 20
MVP: Higher Margin Outlook Will Support Future Earnings Multiple Reassessment
Analysts have trimmed their price target for Medical Developments International to A$2.02 from A$2.27, citing updated assumptions that include a higher discount rate, a lower future P/E and revised expectations for revenue growth and profit margins. Valuation Changes Fair Value: Trimmed from A$2.27 to A$2.02, reflecting a slightly lower assessed value per share.Analysis Article • Dec 01
Medical Developments International Limited (ASX:MVP) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Medical Developments International Limited ( ASX:MVP ) shares have had a horrible month, losing 27% after a relatively...Analysis Article • Oct 15
Medical Developments International Limited's (ASX:MVP) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
The Medical Developments International Limited ( ASX:MVP ) share price has done very well over the last month, posting...Analysis Article • Aug 08
There Is A Reason Medical Developments International Limited's (ASX:MVP) Price Is Undemanding
You may think that with a price-to-sales (or "P/S") ratio of 2.1x Medical Developments International Limited ( ASX:MVP...Analysis Article • Jul 18
Medical Developments International (ASX:MVP) Is In A Strong Position To Grow Its Business
We can readily understand why investors are attracted to unprofitable companies. For example, although...New Narrative • May 14
Targeted Pricing And Penthrox Expansion Will Broaden International Reach
Targeted pricing and efficiency programs are improving margins, expected to enhance earnings and net margins over the next few years.Analysis Article • May 07
Medical Developments International Limited (ASX:MVP) Held Back By Insufficient Growth Even After Shares Climb 33%
Those holding Medical Developments International Limited ( ASX:MVP ) shares would be relieved that the share price has...Analysis Article • Apr 18
Medical Developments International (ASX:MVP) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analysis Article • Mar 16
Take Care Before Jumping Onto Medical Developments International Limited (ASX:MVP) Even Though It's 27% Cheaper
The Medical Developments International Limited ( ASX:MVP ) share price has softened a substantial 27% over the previous...Analysis Article • Jan 30
Benign Growth For Medical Developments International Limited (ASX:MVP) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 1.5x Medical Developments International Limited ( ASX:MVP ) may be sending...Analysis Article • May 13
Positive Sentiment Still Eludes Medical Developments International Limited (ASX:MVP) Following 27% Share Price Slump
To the annoyance of some shareholders, Medical Developments International Limited ( ASX:MVP ) shares are down a...Analysis Article • May 03
Is Medical Developments International (ASX:MVP) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysis Article • Mar 11
Why Investors Shouldn't Be Surprised By Medical Developments International Limited's (ASX:MVP) 28% Share Price Plunge
Medical Developments International Limited ( ASX:MVP ) shareholders won't be pleased to see that the share price has...Analysis Article • Jan 16
Medical Developments International Limited (ASX:MVP) Soars 28% But It's A Story Of Risk Vs Reward
Medical Developments International Limited ( ASX:MVP ) shares have had a really impressive month, gaining 28% after a...Analysis Article • Jan 03
Will Medical Developments International (ASX:MVP) Spend Its Cash Wisely?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analysis Article • Aug 09
Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Analysis Article • Apr 24
We're Keeping An Eye On Medical Developments International's (ASX:MVP) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analysis Article • Jul 04
Is Medical Developments International (ASX:MVP) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysis Article • Mar 04
Some Analysts Just Cut Their Medical Developments International Limited (ASX:MVP) Estimates
The latest analyst coverage could presage a bad day for Medical Developments International Limited ( ASX:MVP ), with...Analysis Article • Mar 05
Medical Developments International Limited (ASX:MVP) Analysts Just Slashed This Year's Estimates
The latest analyst coverage could presage a bad day for Medical Developments International Limited ( ASX:MVP ), with...Analysis Article • Feb 07
If You Had Bought Medical Developments International (ASX:MVP) Shares Five Years Ago You'd Have Earned 56% Returns
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...Analysis Article • Dec 16
Don't Ignore The Fact That This Insider Just Sold Some Shares In Medical Developments International Limited (ASX:MVP)
Some Medical Developments International Limited ( ASX:MVP ) shareholders may be a little concerned to see that the Non...Analysis Article • Dec 10
Medical Developments International Limited's (ASX:MVP) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Medical Developments International's (ASX:MVP) stock is up by a considerable 28% over the past three months. However...Shareholder Returns
| MVP | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 6.4% | 15.6% | -0.2% |
| 1Y | -31.7% | -13.3% | 1.0% |
Return vs Industry: MVP underperformed the Australian Pharmaceuticals industry which returned -13.3% over the past year.
Return vs Market: MVP underperformed the Australian Market which returned 1% over the past year.
Price Volatility
| MVP volatility | |
|---|---|
| MVP Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 9.6% |
| 10% most volatile stocks in AU Market | 17.0% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: MVP has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: MVP's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | n/a | Brent MacGregor | medicaldev.com |
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analgesia during short procedures.
Medical Developments International Limited Fundamentals Summary
| MVP fundamental statistics | |
|---|---|
| Market cap | AU$49.57m |
| Earnings (TTM) | -AU$436.00k |
| Revenue (TTM) | AU$40.64m |
1.2x
P/S Ratio-107.2x
P/E RatioIs MVP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MVP income statement (TTM) | |
|---|---|
| Revenue | AU$40.64m |
| Cost of Revenue | AU$10.08m |
| Gross Profit | AU$30.56m |
| Other Expenses | AU$30.99m |
| Earnings | -AU$436.00k |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 75.19% |
| Net Profit Margin | -1.07% |
| Debt/Equity Ratio | 0% |
How did MVP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/03 14:07 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medical Developments International Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martyn Jacobs | Bell Potter |
| Martyn Jacobs | Canaccord Genuity |
| Dan Hurren | MST Financial Services Pty Limited |